What major FDA approvals and leadership changes occurred in pharma this week?

This week saw Allogene Therapeutics’ CEO David Chang step down, with CMO Zachary Roberts taking over July 1. The FDA approved AbbVie’s ADC Decnupaz for a rare blood cancer, cleared AstraZeneca’s Imfinzi with BCG for bladder cancer, and began reviewing BridgeBio’s BBP‑418 for limb‑girdle muscular dystrophy.